Table 1.
Patient baseline characteristics.
| Continuous dosing | Intermittent dosing | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| PDAC | Ovarian cancer | Other solid tumors | Total | PDAC | Ovarian cancer | Other solid tumors | Total | Total | |
| Safety population, n | 34 | 5 | 15 | 54 | 3 | 9 | 7 | 19 | 73 |
| Age (y), mean (SD) | 61.6 (10.3) | 43.8 (16.4) | 59.0 (14.1) | 59.2 (12.9) | 67.0 (10.0) | 58.2 (10.2) | 61.9 (14.0) | 60.9 (11.5) | 59.7 (12.5) |
| Sex, female, n (%) | 15 (44.1%) | 5 (100%) | 13 (86.7%) | 33 (61.1%) | 3 (100%) | 9 (100%) | 5 (71.4%) | 17 (89.5%) | 50 (68.5%) |
| Prior lines of cancer therapy, mean (SD) | 2.6 (1.0) | 4.0 (1.2) | 3.9 (2.2) | 3.1 (1.5) | 3.7 (1.5) | 4.0 (1.3) | 3.6 (1.6) | 3.8 (1.4) | 3.3 (1.5) |
| Prior taxane, n (%) | 26 (76.5%) | 5 (100%) | 10 (66.7%) | 41 (75.9%) | 3 (100%) | 9 (100%) | 2 (28.6%) | 14 (73.7%) | 55 (75.3%) |
| Response evaluable, n | 26 | 4 | 11 | 41 | 1 | 9 | 6 | 16 | 57 |
| Prior taxane, n (%) | 20 (76.9%) | 4 (100%) | 7 (63.6%) | 31 (75.6%) | 1 (100%) | 9 (100%) | 1 (16.7%) | 11 (68.8%) | 42 (73.7%) |
| Dose-limiting toxicity evaluable, n | 23 | 4 | 10 | 37 | 3 | 6 | 5 | 14 | 51 |
Note: Cancer types in the other solid tumors group included breast (3/15, 20.0%), triple-negative breast cancer or melanoma (2/15, 13.3% each), and pancreatic, sarcoma, cervical, and rectal cancer (1/15, 6.7% each). Ovarian cancer includes fallopian tube or primary peritoneal cancer.